Welcome to Coulter Partners Global (English)

23 January 2023

Top hires for VC & PE portfolio companies Q4-2022

Search Highlights

Recent top global hires for Venture Capital and Private Equity backed companies, covering a broad range of disciplines and sectors across Life Sciences, Health, and Tech.

This quarter’s successful placements include:

Function Focus area Location
CEO Regenerative medicine UK
CEO Implantable cardiac devices France
Chief Business Officer Neurodegenerative diseases Netherlands
Chief Medical Officer Age-related therapeutics US
Chief Financial Officer RNA-based therapeutics Germany
SVP, GM Biosurgery & EMEA Sales Surgical equipment Belgium
Head of Regulatory Affairs In vivo gene editing US
Country CEO Veterinary services Nordics
UK General Manager Digital devices and therapeutics US
VP Immunology / Translation Small molecule therapeutics UK
VP Global Leader of Manufacturing and Operations DNA sequencing UK
Head of Product AI-enabled analytics Belgium
2 x Board Directors Infectious Diseases UK
Chair Active Pharmaceutical Ingredients (APIs) Switzerland

Newly opened projects include:

Function Focus area Location
CEO RNA vaccines UK
CEO Vaccines Switzerland
CEO Specialist CRO Australia
Chief Business Officer Precision medicines US
Chief Scientific Officer Retinal vascular diseases Nordics
Chief Technology Officer AAV gene therapy US
Chief of Staff Ophthalmic medical devices France
Chief Technology & Operations Officer Plant-based foods Nordics
VP, Antibody Engineering & Protein Sciences Drug discovery services US
Head of Translational Medicine Cell therapy biotech Switzerland
VP Business Development Oncology Quantum physics enabled drug development US
Investment Manager Digital Health VC investor Netherlands
Chair AI for drug discovery Central & Eastern Europe


A new version of Coulter Partners is available.